MRSN - Mersana Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Mersana Therapeutics, Inc.

840 Memorial Drive
Cambridge, MA 02139
United States
617-498-0020
http://www.mersana.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Ms. Anna ProtopapasPres, CEO & Director727kN/A1964
Dr. Timothy B. LowingerChief Scientific & Technology Officer516kN/A1964
Mr. Mikhail Papisov Ph.D.Co-FounderN/AN/AN/A
Mr. Brian C. DeSchuytnerSr. VP of Fin. & Product StrategyN/AN/AN/A
Mr. Wayne FosterVP of Fin. & Principal Accounting OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Corporate Governance

Mersana Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.